Strategic Research and Development Investment Decisions in the Pharmaceutical Industry

References

• Aghion P, Blundell R, Griffith R, Howitt P, Prantl S (2004) Entry and productivity growth: Evidence from microlevel panel data. J. Eur. Econom. Assoc. 2(2–3):265–276.Crossref, Google Scholar
• Arcidiacono P, Ellickson PB (2011) Practical methods for estimation of dynamic discrete choice models. Annual Rev. Econom. 3:363–394.Crossref, Google Scholar
• Arcidiacono P, Miller RA (2011) Conditional choice probability estimation of dynamic discrete choice models with unobserved heterogeneity. Econometrica 7(6):1823–1868.Google Scholar
• Azoulay P (2002) Do pharmaceutical sales respond to scientific evidence? J. Econom. Management Strategy 11(4):551–594.Crossref, Google Scholar
• Bajari P, Benkard CL, Levin J (2007) Estimating dynamic models of imperfect competition. Econometrica 75(5):1331–1370.Crossref, Google Scholar
• Berry S, Pakes A (2007) The pure characteristics demand model. Internat. Econom. Rev. 48(4):1193–1225.Crossref, Google Scholar
• Bresnahan TF, Reiss PC (1991a) Empirical models of discrete games. J. Econometrics 48(1–2):57–81.Crossref, Google Scholar
• Bresnahan TF, Reiss PC (1991b) Entry and competition in concentrated markets. J. Political Econom. 99(5):997–1009.Crossref, Google Scholar
• Borkovsky R, Goldfarb A, Haviv A, Moorthy S (2017) Measuring and understanding brand value in a dynamic model of brand management. Marketing Sci. 36(4):471–499.Link, Google Scholar
• Budish E, Roin BN, Williams H (2015) Do firms underinvest in long-term research? Evidence from cancer clinical trials. Amer. Econom. Rev. 105(7):2044–2085.Crossref, Google Scholar
• Califf RM (2016) 21st Century Cures Act: Making progress on shared goals for patients. FDA Voice Blog, December 13, https://www.prnewswire.com/news-releases/fda-voice-blog-21st-century-cures-act-making-progress-on-shared-goals-for-patients-300377752.html.Google Scholar
• Caves RE, Whinston MD, Hurwitz MA (1991) Patent expiration, entry, and competition in the U.S. pharmaceutical industry: An exploratory analysis. Brookings Papers Econom. Activity: Microeconom. 1991(22):1–66.Crossref, Google Scholar
• C.H. (2011) Big Pharma’s gripes about the FDA. Schumpeter (blog), July 1, https://www.economist.com/schumpeter/2011/07/01/big-pharmas-gripes-about-the-fda.Google Scholar
• Ching A (2010a) A dynamic oligopoly structural model for the prescription drug market after patent expiration. Internat. Econom. Rev. 51(4):1175–1207.Crossref, Google Scholar
• Ching A (2010b) Consumer learning and heterogeneity: Dynamics of demand for prescription drugs after patent expiration. Internat. J. Indust. Organ. 28(6):619–638.Crossref, Google Scholar
• Ching A, Ishihara M (2010) The effects of detailing on prescribing decisions under quality uncertainty. Quant. Marketing Econom. 8(2):123–165.Crossref, Google Scholar
• Ching A, Lim H (2020) A structural model of correlated learning and late-mover advantages: The case of statins. Management Sci. 66(3):1095–1123.Link, Google Scholar
• Ching A, Clark R, Horstmann I, Lim H (2016) The effects of publicity on demand: The case of anti-cholesterol drugs. Marketing Sci. 35(1):158–181.Abstract, Google Scholar
• Cockburn I, Henderson R (1995) Racing to invest? The dynamics of competition in ethical drug discovery. J. Econom. Management Strategy 3(3):481–519.Crossref, Google Scholar
• DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: New estimates of drug development costs. J. Health Econom. 22(2):151–185Crossref, Google Scholar
• Doraszelski U (2003) An R&D race with knowledge accumulation. RAND J. Econom. 34(1):20–42.Crossref, Google Scholar
• Doraszelski U, Pakes A (2007) A framework for applied dynamic analysis in IO. Armstrong M, Porter R, eds. Handbook of Industrial Organization, vol. 3 (Elsevier, New York), 1887–1966.Google Scholar
• Dubé J, Hitsch G, Manchanda P (2005) An empirical model of advertising dynamics. Quant. Marketing Econom. 3(2):107–144.Crossref, Google Scholar
• Ellickson PB, Misra S, Nair H (2012) Repositioning dynamics and pricing strategy. J. Marketing Res. 49(6):750–772.Crossref, Google Scholar
• Ellison G, Ellison SF (2011) Strategic entry deterrence and the behavior of pharmaceutical incumbents prior to patent expiration. Amer. Econom. J. Microeconom. 3(1):1–36.Crossref, Google Scholar
• FDA (Food and Drug Administration) (2016) New drug applications (NDA) and biologic license applications (BLA) approval times, 1993–2016. Accessed July 1, 2016, https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NDAandBLAApprovalReports/UCM540942.pdf.Google Scholar
• FDA (Food and Drug Administration) (2017) Prescription Drug User Fee amendments. Accessed July 1, 2017, https://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/.Google Scholar
• Fox M (2015) This bill increases funding for NIH and FDA, so why doesn’t everyone love it? NBC News (July 10), https://www.nbcnews.com/health/health-news/bill-raises-funding-nih-fda-so-why-doesn-t-everyone-n390241.Google Scholar
• Gaffney A (2015) 10 proposals worth paying attention to in the 21st Century Cures Act. Regulatory Focus (January 30), https://www.raps.org/regulatory-focus%E2%84%A2/news-articles/2015/1/10-proposals-worth-paying-attention-to-in-the-21st-century-cures-act.Google Scholar
• Gilbert R (2006) Looking for Mr. Schumpeter: Where are we in the competition-innovation debate? Innovation Policy Econom. 6:159–215.Google Scholar
• Goettler RL, Gordon B (2011) Does AMD spur Intel to innovate more? J. Political Econom. 119(6):1141–1200.Crossref, Google Scholar
• Goettler RL, Gordon B (2014) Competition and product innovation in dynamic oligopoly. Quant. Marketing Econom. 12(1):1–42.Crossref, Google Scholar
• Gowrisankaran G, Town R (1997) Dynamic equilibrium in the hospital industry. J. Econom. Management Strategy 6(1):45–74.Crossref, Google Scholar
• Grabowski H, Kyle M (2007) Generic competition and market exclusivity periods in pharmaceuticals. Management Decision Econom. 28(4–5):491–502.Crossref, Google Scholar
• Hauser J, Tellis GJ, Griffin A (2006) Research on innovation: A review and agenda for Marketing Science. Marketing Sci. 25(6):687–717.Link, Google Scholar
• Hiltzik M (2016) The 21st Century Cures Act: A huge handout to the drug industry disguised as a pro-research bounty. Los Angeles Times (December 5), https://www.latimes.com/business/hiltzik/la-fi-hiltzik-21st-century-20161205-story.html.Google Scholar
• Hitsch GJ (2006) An empirical model of optimal dynamic product launch and exit under demand uncertainty. Marketing Sci. 25(1):25–50.Link, Google Scholar
• Hotz VJ, Miller RA (1993) Conditional choice probabilities and the estimation of dynamic models. Rev. Econom. Stud. 60(3):497–529.Crossref, Google Scholar
• Liu Q, Gupta S, Venkataraman S, Liu H (2016) An empirical model of drug detailing: Dynamic competition and policy implications. Management Sci. 62(8):2321–2340.Link, Google Scholar
• MacDonald JM (1994) Does import competition force efficient production? Rev. Econom. Statist. 76(4):721–727.Crossref, Google Scholar
• Mestre-Ferrandiz J, Sussex J, Towse A (2012) The R&D Cost of a New Medicine (Office of Health Economics, London).Google Scholar
• National Institutes of Health (2019) Estimates of funding for various research, condition, and disease categories (RCDC). Research Portfolio Online Reporting Tools (April 19), https://report.nih.gov/categorical_spending.aspx.Google Scholar
• Ouellette LL (2010) How many patents does it take to make a drug—Follow-on pharmaceutical patents and university licensing. Michigan Telecomm. Tech. Law Rev. 17(1):299–336.Google Scholar
• Pesendorfer M, Schmidt-Dengler P (2008) Asymptotic least squares estimators for dynamic games. Rev. Econom. Stud. 75(3):901–928.Crossref, Google Scholar
• Rappeport A (2011) Medtronic chief rues US approval process. Financial Times (October 2), https://www.ft.com/content/5780e98a-ebb3-11e0-943a-00144feab49a.Google Scholar
• Reiffen D, Ward MR (2005) Generic drug industry dynamics. Rev. Econom. Statist. 87(1):37–49.Crossref, Google Scholar
• Rust J (1994) Structural estimation of Markove decision processes. Engle RF, McFadden D, eds. Handbook of Econometrics (Elsevier, Amsterdam), 3081–3143.Google Scholar
• Ryan SP (2012) The costs of environmental regulation in a concentrated industry. Econometrica 80(3):1019–1061.Crossref, Google Scholar
• Shen Q, Villas-Boas JM (2010) Strategic entry before demand takes off. Management Sci. 56(8):1259–1271.Link, Google Scholar
• Sood A, Kappe E, Stremersch S (2014) The commercial contribution of clinical studies for pharmaceutical drugs. Internat. J. Res. Marketing 31(1):65–77.Crossref, Google Scholar
• Vitorino MA (2014) Understanding the effect of advertising on stock returns and firm value: Theory and evidence from a structural model. Management Sci. 60(1):227–245.Link, Google Scholar